A Phase 1 interventional study of Placebo Single Dose (SD) and BI 1015550 Single Dose (SD) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Part 1 (SRD (Single-rising dose)):
The primary objective of this trial part is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of single rising doses.
Secondary objectives are the exploration of the pharmacokinetics of BI 1015550 after single dosing.
Part 2 (MRD (Multiple-rising dose)):
In Part 2, the primary objective is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of multiple rising doses.
Secondary objectives are the exploration of the pharmacokinetics of BI 1015550 after multiple dosing.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received single dose of placebo tablet matching to BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1
Drug: Placebo Single Dose (SD)
Subjects received placebo tablet matching to BI 1015550 twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14
Drug: Placebo Multiple Dose (MD)
Subjects received single dose of BI 1015550 36 mg (6 tablets of 6 mg) orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1
Drug: BI 1015550 Single Dose (SD)
Subjects received single dose of BI 1015550 48 mg (8 tablets of 6 mg) orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours (h) on day 1
Drug: BI 1015550 Single Dose (SD)
Subjects received BI 1015550 6 mg (1 tablet of 6 mg) twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14
Drug: BI 1015550 Multiple Dose (MD)
Subjects received BI 1015550 12 mg (2 tablets of 6 mg) twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal. Subjects were treated for 14 days and received a single morning dose on Day 1, followed by 11 day treatment and a single morning dose on Day 14
Drug: BI 1015550 Multiple Dose (MD)
Subjects received single dose of placebo tablet matching to BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours
Subjects received single dose of BI 1015550 orally with 240 milligram (mL) of water after an overnight fast of at least 10 hours
Also known as: Nerandomilast, JASCAYD®
Subjects received placebo tablet matching to BI 1015550 twice daily (bid) orally with 240 milligram (mL) of water after a moderate fat meal.
Subjects received BI 1015550 twice daily (bid) starting on Day 3 orally with 240 milligram (mL) of water after a moderate fat meal.
Also known as: Nerandomilast, JASCAYD®
Number of Subjects With Drug-related Adverse Events (AEs)
Number of subjects with drug-related Adverse Events (AEs).
Time frame: For SRD: From the administration of study medication until 7 days, up to day 8. For MRD: From the first administration of study medication until 7 days after the last administration of study medication, i.e. up to 21 days after first drug administration.
Part 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Part 1 (SRD): Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration
Part 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)
Part 1 (SRD): Maximum measured concentration of the BI 1015550 in plasma (Cmax).
Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 48:00, 72:00, 96:00, 120:00 hours after drug administration
Part 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1)
Part 2 (MRD) - After the first dose : Area under the concentration-time curve of the BI 1015550 in plasma over a uniform dosing interval tau after administration of the first dose (AUCτ,1).
Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration
Part 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)
Part 2 (MRD) - After the first dose : Maximum measured concentration of the BI 1015550 in plasma (Cmax).
Time frame: Pharmacokinetic samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration
Part 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)
Part 2 (MRD) - After the last dose: Area under the concentration-time curve of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (AUCtau,ss).
Time frame: Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 311:55, 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00
Part 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss)
Part 2 (MRD) - After the last dose: Maximum measured concentration of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (Cmax,ss).
Time frame: Pharmacokinetic samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00
Part 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax)
Part 2 (MRD) - Accumulation ratio based on Cmax,ss (RA,Cmax). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00.
Time frame: Up to 504 hours following first drug administration, Please find the time frame in description section.
Part 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC)
Part 2 (MRD) - Accumulation ratio based on AUC0-tau (RA,AUC). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00.
Time frame: Up to 324 hours following first drug administration, Please find the time frame in description section.
Safety, tolerability, and pharmacokinetics of BI 1015550 in healthy male subjects. Single rising dose (SRD) part: Partially randomized within dose groups, placebo-controlled, single-blind, parallel-group design; Multiple rising dose (MRD) part: Partially randomized within dose groups, placebo-controlled, double-blind, parallel-group design.
| Milestone | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 milligram (mg) Single Dose (SD) | BI 1015550 48 milligram (mg) Single Dose (SD) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|---|---|---|---|
| Started | 6 | 8 | 6 | 6 | 8 | 8 |
| Completed | 6 | 8 | 6 | 5 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
Number of subjects with drug-related Adverse Events (AEs).
| Participants | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 milligram (mg) Single Dose (SD) | BI 1015550 48 milligram (mg) Single Dose (SD) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|---|---|---|---|
| Number of Subjects With Drug-related Adverse Events (AEs) | 1 | 1 | 2 | 4 | 2 | 4 |
Part 1 (SRD): Area under the concentration-time curve of the BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).
| nanomole*hour/liter (nmol∙h/L) | BI 1015550 36 milligram (mg) Single Dose (SD) | BI 1015550 48 milligram (mg) Single Dose (SD) |
|---|---|---|
| Part 1 (SRD): Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 5910 ± 21.2 | 8700 ± 17.2 |
Part 1 (SRD): Maximum measured concentration of the BI 1015550 in plasma (Cmax).
| nanomole/liter (nmol/L) | BI 1015550 36 milligram (mg) Single Dose (SD) | BI 1015550 48 milligram (mg) Single Dose (SD) |
|---|---|---|
| Part 1 (SRD): Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax) | 710 ± 20.7 | 955 ± 15.5 |
Part 2 (MRD) - After the first dose : Area under the concentration-time curve of the BI 1015550 in plasma over a uniform dosing interval tau after administration of the first dose (AUCτ,1).
| nanomole*hour/liter (nmol∙h/L) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - After the First Dose : Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCτ,1) | 564 ± 24.8 | 1370 ± 15.9 |
Part 2 (MRD) - After the first dose : Maximum measured concentration of the BI 1015550 in plasma (Cmax).
| nanomole/liter (nmol/L) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - After the First Dose : Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax) | 103 ± 28.2 | 229 ± 29.9 |
Part 2 (MRD) - After the last dose: Area under the concentration-time curve of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (AUCtau,ss).
| nanomole*hour/liter (nmol∙h/L) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - After the Last Dose: Area Under the Concentration-time Curve of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss) | 1050 ± 25.7 | 2300 ± 15.8 |
Part 2 (MRD) - After the last dose: Maximum measured concentration of the BI 1015550 in plasma at steady state over a uniform dosing interval tau (Cmax,ss).
| nanomole/liter (nmol/L) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - After the Last Dose: Maximum Measured Concentration of the BI 1015550 in Plasma at Steady State Over a Uniform Dosing Interval Tau (Cmax,ss) | 164 ± 21.3 | 348 ± 14.1 |
Part 2 (MRD) - Accumulation ratio based on Cmax,ss (RA,Cmax). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00, 34:00, 47:55 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00, 336:00, 346:00, 360:00, 384:00, 408:00, 432:00, 456:00, 480:00, 504:00.
| Ratio | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - Accumulation Ratio Based on Cmax,ss (RA,Cmax) | 1.60 ± 35.0 | 1.52 ± 23.6 |
Part 2 (MRD) - Accumulation ratio based on AUC0-tau (RA,AUC). First Dose PK samples were taken within 2:00 hours before and 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00 hours after drug administration. Last Dose PK samples were taken within 5 minutes pre-dose and at hours 312:15, 312:30, 312:45, 313:00, 313:15, 313:30, 314:00, 315:00, 316:00, 318:00, 320:00, 324:00.
| Ratio | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|
| Part 2 (MRD) - Accumulation Ratio Based on AUC0-tau (RA,AUC) | 1.85 ± 9.91 | 1.68 ± 14.8 |
Collected over Adverse events: For SRD: From the administration of study medication until 7 days, up to day 8. For MRD: From the first administration of study medication until 7 days after the last administration of study medication, i.e. up to 21 days after first drug administration. All-cause mortality: for SRD, up to 9 days, for MRD, up to 28 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Single Dose (SD) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo Multiple Dose (MD) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| BI 1015550 36 milligram (mg) Single Dose (SD) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| BI 1015550 48 milligram (mg) Single Dose (SD) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Event | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 milligram (mg) Single Dose (SD) | BI 1015550 48 milligram (mg) Single Dose (SD) | BI 1015550 6 milligram (mg) twice daily Multiple Dose (MD) | BI 1015550 12 milligram (mg) twice daily Multiple Dose (MD) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/6 | 1/8 | 1/6 | 3/6 | 2/8 | 3/8 |
| Abdominal distensionGastrointestinal disorders | 0/6 | 1/8 | 0/6 | 1/6 | 0/8 | 0/8 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/8 | 1/6 | 0/6 | 0/8 | 0/8 |
| ConstipationGastrointestinal disorders | 0/6 | 0/8 | 1/6 | 0/6 | 0/8 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/8 | 1/6 | 0/6 | 1/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/6 | 0/8 | 0/6 | 0/6 | 1/8 | 0/8 |
| NasopharyngitisInfections and infestations | 0/6 | 0/8 | 0/6 | 1/6 | 0/8 | 0/8 |
| Ligament sprainInjury, poisoning and procedural complications | 0/6 | 0/8 | 0/6 | 1/6 | 0/8 | 0/8 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 0/8 | 1/6 | 0/6 | 0/8 | 0/8 |
| DizzinessNervous system disorders | 0/6 | 0/8 | 1/6 | 0/6 | 0/8 | 0/8 |
Treated set (TS): This subject set included all subjects who had received at least 1 dose of trial medication.
| Age, Continuous(Years) | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 Milligram (mg) Single Dose (SD) | BI 1015550 48 Milligram (mg) Single Dose (SD) | BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD) | BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 34.3 ± 7.9 | 33.8 ± 6.6 | 32.2 ± 6.6 | 38.2 ± 7.9 | 35.8 ± 8.7 | 33.5 ± 5.3 | 34.6 ± 7.0 |
| Sex: Female, Male(Participants) | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 Milligram (mg) Single Dose (SD) | BI 1015550 48 Milligram (mg) Single Dose (SD) | BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD) | BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 8 | 6 | 6 | 8 | 8 | 42 |
| Race (NIH/OMB)(Participants) | Placebo Single Dose (SD) | Placebo Multiple Dose (MD) | BI 1015550 36 Milligram (mg) Single Dose (SD) | BI 1015550 48 Milligram (mg) Single Dose (SD) | BI 1015550 6 Milligram (mg) Twice Daily Multiple Dose (MD) | BI 1015550 12 Milligram (mg) Twice Daily Multiple Dose (MD) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| White | 6 | 6 | 5 | 6 | 8 | 8 | 39 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Jan 2018, 5 months.
Results were first posted in Nov 2025, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast